SABS is the ticker for SAB Biotherapeutics, Inc., a Nasdaq-listed biotech developing fully-human polyclonal antibody therapies. Its lead program, SAB-142, targets stage 3 (recent-onset) type 1 diabetes and is in Phase 2b development. Because the company is pre-revenue, analyst price targets are driven almost entirely by the estimated value of that single asset.
Reviewing current, attributable targets yields a range from a low of $6 (Craig-Hallum) to a high of $16 (Chardan Capital, which raised its target from $14). In between sit Oppenheimer at $14, Barclays at $13, UBS at $12, Citi at $11, Jefferies at $11, H.C. Wainwright at $10, and Guggenheim at $15. The arithmetic mean of these verified targets is approximately $12, which is the central target used throughout this article. It is a calculated average of individual targets, not an officially published consensus, and the unusually wide $6-to-$16 spread shows how much analysts disagree on the probability and size of SAB-142's success.
Coverage momentum has been notably positive. Jefferies initiated with a Buy in May 2026, Citi initiated with a Buy and an $11 target, calling the program a potential paradigm shift in type 1 diabetes treatment, and Barclays initiated with an Overweight rating and a $13 target, citing the large market for SAB-142. Guggenheim's Yatin Suneja has reiterated a $15 target, while H.C. Wainwright's Emily Bodnar raised her target to $10 from $7.
The stock recently traded near $3.05, with a 52-week range of roughly $2.44 to $5.15 and a market capitalization around $278 million. Reaching $12 would require a gain of approximately 290%, a very large move that would effectively re-rate the company from a deeply speculative, sub-$300 million name to a materially higher valuation.
There is no meaningful earnings bridge to support that path in the near term: the company is unprofitable, with a trailing EPS (earnings per share) of about -$1.29 and consensus estimates of roughly -$1.21 for fiscal 2026 and -$0.80 for fiscal 2027. In practice, the move toward the target would have to be driven by binary clinical events rather than steady operating improvement, which is why the stock has been volatile and why the analyst range is so wide.
The central support is clinical. Positive Phase 2b data for SAB-142 in stage 3 type 1 diabetes, if it demonstrates meaningful preservation of beta-cell function or reduced insulin dependence, could justify a substantial re-rating given the size of the type 1 diabetes market and the limited disease-modifying options available. Recent analyst initiations from Jefferies, Citi, and Barclays, along with upward target revisions from Chardan Capital and H.C. Wainwright, indicate growing institutional interest and a strengthening bull case. The company's DiversitAb platform, which produces fully-human antibodies in genetically engineered cattle, is also viewed as a differentiated manufacturing and discovery asset.
The principal risk is clinical failure or ambiguous data. The company reported a GAAP net loss of roughly $22.5 million in the quarter ended June 30, 2026, wider than the prior-year period, underscoring its cash burn. As a pre-revenue biotech, SABS may need additional capital, creating dilution risk that can weigh on the share price even when the science advances. Sector conditions also matter: risk appetite for small-cap, pre-revenue biotech can shift quickly, and a broad rotation away from speculative healthcare names could compress the multiple that investors are willing to pay, independent of company-specific progress.
The stock has been rangebound and volatile, with a 52-week low near $2.44 and a 52-week high near $5.15. The $5 area represents both a psychological level and the prior high, and it is the first major resistance zone the stock would need to reclaim before the $12 target could even become technically relevant. The $12 objective sits well above the 52-week high, meaning the stock would need a sustained, fundamentally driven breakout rather than a simple recovery toward prior levels.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms may differ, and no explicit timing was stated for every target reviewed here. The most important upcoming items are the next earnings report, estimated for mid-November 2026, and any updates on SAB-142's Phase 2b trial, including data readouts and enrollment progress. Investors should also monitor analyst target revisions, financing announcements, and shifts in sentiment toward small-cap biotech.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like SABS, such tools can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual screening. Traders evaluating this and other tickers may find the signals a useful complement to fundamental research.
The $12 central target reflects the average of a wide $6-to-$16 analyst range, and it implies a roughly 290% move from the recent price near $3.05, an objectively very large advance. The bull case rests on positive Phase 2b data for SAB-142 and a large addressable market in type 1 diabetes, reinforced by a wave of recent Buy initiations. The bear case centers on clinical risk, ongoing losses, and potential dilution. Whether the stock can approach $12 ultimately depends on clinical results that have not yet been delivered, and no target, including the calculated average, should be treated as a forecast or guarantee.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SABS has been loosely correlated with REVB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SABS jumps, then REVB could also see price increases.
| Ticker / NAME | Correlation To SABS | 1D Price Change % | ||
|---|---|---|---|---|
| SABS | 100% | -0.97% | ||
| REVB - SABS | 48% Loosely correlated | -3.07% | ||
| INKT - SABS | 47% Loosely correlated | -1.38% | ||
| CYPH - SABS | 46% Loosely correlated | -9.75% | ||
| VYGR - SABS | 39% Loosely correlated | -8.29% | ||
| CABA - SABS | 36% Loosely correlated | -3.33% | ||
More | ||||